Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

doi 10.1021/acsmedchemlett.6b00005.s001
Full Text
Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

English

The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models

Science advances
Multidisciplinary
2018English

A Brain-Penetrant MET Inhibitor Achieves Responses in Glioblastoma

Cancer Discovery
Oncology
2018English

A Brain Penetrant Mutant IDH1 Inhibitor Provides in Vivo Survival Benefit

Scientific Reports
Multidisciplinary
2017English

The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2020English

Pre-Clinical Activity of Targeting the PI3K/Akt/mTOR Pathway in Burkitt Lymphoma

Oncotarget
Oncology
2018English

GDC: Group Discovery Using Co-Location Traces

2010English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica
MedicinePharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy